LARIMAR THERAPEUTICS INC (LRMR)

Company Profile

Larimar Therapeutics, Inc. Is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics mitochondrial disorders and Friedreich's ataxia. The company is headquartered in Bala Cynwyd, Pennsylvania and currently employs 26 full-time employees. The company went IPO on 2014-06-19. The Company’s lead compound, CTI-1601, is being developed as a potential treatment for Friedreichs ataxia (FA). CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with FA. FA is a rare, progressive, and fatal disease in which patients are unable to produce sufficient frataxin (FXN) due to a genetic abnormality. The company also focuses on using its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. Its CPP platform enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets.

Company Info

LARIMAR THERAPEUTICS INC

Three Bala Plaza East. Suite 506

Bala Cynwyd PENNSYLVANIA 19004

P: 18445119056

CEO: Carole Ben-Maimon

Employees: 26

Website: https://larimartx.com/